Maintaining momentum for a rush of 2021 IPOs already on pace to beat 2020's record number, new offerings from Graphite Bio Inc., GH Research plc and Elevation Oncology Inc. raised nearly $500 million altogether on Friday. While shares of the first two fared well, climbing in their debuts, Elevation's shares (NASDAQ:ELEV) fell from $16 debut to $11.44 at the close, a 28.5% decline.

Vida Ventures, the venture capital firm co-founded by CAR T pioneer Arie Belldegrun, has closed an oversubscribed $825 million fund, bringing the total amount of assets under management to more than $1.7 billion.

Adela snapped up $60 million in a series A financing round to commercialize its blood test for cancer detection and disease monitoring. At the same time, the company announced its name change from Dnamx Inc. The Adela system profiles all methylated DNA fragments in a blood sample, allowing it to determine the tissue of origin early in development of a malignancy and potentially simplifying screening across all cancer types.

Quanta Dialysis Technologies Ltd. raised $245 million in a series D round led by Glenview Capital. The funds will be used to accelerate commercialization of the company’s SC+ portable hemodialysis system. Novo Holdings co-led the oversubscribed and upsized financing, with support from Blackrock, Eldridge, Sands Capital, Millennium Management, Monashee Investment Management LLC, Puhua Capital, Segulah Medical and Ancora, alongside Orlando Health, an integrated delivery network.

Tvardi Therapeutics Inc., a company targeting a protein essential to cancer cells' survival and immune evasion, closed a $74 million series B financing. The round will help it advance candidates through multiple midstage trial readouts in cancer and fibrosis, the Houston-based company said.